Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 6Plasma cell 1

Conditions

Multiple Myeloma 181Recurrence 26Neoplasms, Plasma Cell 16Smoldering Multiple Myeloma 4Neoplasms 4Lymphoma 4Leukemia, Plasma Cell 3Leukemia 2Disease 2Waldenstrom Macroglobulinemia 1Small Cell Lung Carcinoma 1Renal Insufficiency 1Plasmacytoma 1Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Kidney Failure, Chronic 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Hematologic Neoplasms 1Graft vs Host Disease 1Carcinoma, Non-Small-Cell Lung 1Bone Marrow Neoplasms 1Blast Crisis 1Anemia 1Amyloidosis 1

Interventions

fludarabine phosphate 38Peripheral Blood Stem Cell Transplantation 35Whole-Body Irradiation 30Mycophenolic Acid 29Cyclophosphamide 27Tacrolimus 21Cyclosporine 20Busulfan 17Antilymphocyte Serum 14Methotrexate 13Melphalan 12Sirolimus 9Radiotherapy 8Filgrastim 8Etoposide 8Cyclosporins 8Cord Blood Stem Cell Transplantation 6Transplantation 5Methylprednisolone 5Bortezomib 5sargramostim 4Therapeutics 4Everolimus 4Epoetin Alfa 4Cytarabine 4Carboplatin 4thymoglobulin 3fludarabine 3Thiotepa 3Rituximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × carfilzomib × Plasma cell × Clear all
NCT00150462 2017-05-02

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

Amgen

Phase 1 Completed
48 enrolled 26 charts
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡